Mologen AG
Quick facts
Phase 3 pipeline
- MGN1703 treatment · Oncology
MGN1703 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: